Johnson & Johnson's single-dose vaccine 66% effective in global trial

Johnson & Johnson's single-dose vaccine 66% effective in global trial

In the trial of almost 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.

As for hospitalizations and deaths, the vaccine candidate demonstrated "complete protection" 28 days after vaccination, with no such cases reported.

J&J said Friday that in the USA and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective - 85% - against the most serious symptoms.

Benefits include that it only requires one dose - as opposed to Moderna and Pfizer's two-dose inoculations - and that it can be stored in a regular refrigerator.

"Gambling on one dose was certainly worthwhile", Dr Mathai Mammen, global research chief for J&J's Janssen Pharmaceutical unit, told The Associated Press.

These extremely encouraging trial results suggest another powerful vaccine against coronavirus could soon be within reach.

Nadhim Zahawi, the United Kingdom government minister responsible for the vaccine rollout, said: "Having taken part in Novavax's vaccine trial myself, I am particularly thrilled to see such positive results". According to the Associated Press, the vaccine was 72% effective in preventing moderate to severe cases of COVID-19 in the USA, while only 57% effective in South Africa.

"Moderate" COVID-19 disease included one or more of the following: evidence of pneumonia, deep vein thrombosis, shortness of breath or abnormal blood oxygen saturation above 93%, abnormal respiratory rate (≥20); or two or more systemic symptoms suggestive of COVID-19.

"What we mean by severe COVID is feeling particularly sick at home".

Eighty-five percent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19.

US Warns of 'Heightened Threat Environment' from Extremists Emboldened by Capitol Attack
It also noted that some extremists "may be emboldened by the January 6, 2021, breach of the U.S. Capitol Building in Washington , D.C., to target elected officials and government facilities".

Scientists have been even more anxious about a variant first discovered in South Africa that carries different mutations.

"I think it is possible to vaccinate every adult by September or at least have offered the vaccine to every adult by September", he said.

Pfizer and Moderna vaccines rely on technology that has not been used in previous vaccines, but the Novavax jab uses a more traditional method of recreating part of the spike protein of the virus to stimulate the immune system. The Johnson & Johnson vaccine uses DNA and a modified, weakened version of a cold virus to gain entry into human cells.

It then safely carries part of the coronavirus's genetic code into the body.

Expiration deadlines. The earliest phases of Covid-19 vaccine distribution in some instances have left doctors, nurses, and health officials scrambling to inoculate Americans. "We will alert you as to when you're going to get your vaccine", he said.

During trials, onset of protection was observed as early as 14 days after a single-dose vaccination.

"'I would much prefer only to have to go in to get my one shot rather than to have to go in a month or three weeks later to get my second shot", he said.

The PM welcomed the "good news" and said the UK's medicines regulator would now assess the vaccine. The U.S. already had a contract to purchase 100 million doses from the company.

CBS News asked Dr. Mammen about reports of production delays.

Johnson & Johnson's data still needs to undergo review by the FDA.

Related Articles